TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B Share Price
Certificat
DE000SU0XX41
| Delayed Deutsche Boerse AG 20:42:54 29/05/2024 BST | ||
| 2.61 EUR | +1.95% |
|
| Current month | -8.42% | ||
| 1 month | -15.26% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 29/05/24 | 2.61 | +1.95% |
| 28/05/24 | 2.56 | +1.19% |
| 27/05/24 | 2.53 | +4.98% |
| 24/05/24 | 2.41 | -0.41% |
| 23/05/24 | 2.42 | -4.72% |
Delayed Quote Deutsche Boerse AG
Last update May 29, 2024 at 08:42 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SU0XX4 |
| ISIN | DE000SU0XX41 |
| Date issued | 19/10/2023 |
| Strike | 1,111 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.55 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.31 € |
|---|---|
| Lowest since issue | 2.23 € |
| Spread | 0.01 € |
| Spread % | 0.39% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
911.5
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.25%
- Stock Market
- Certificates
- Certificat
